Serum vascular endothelial growth factor receptor 3 as a potential biomarker in psoriasis

Xia, Hong; Jiang, Shan; Marmolejo, Nancy; Vangipuram, Ramya; Ramos-Rojas, Elmira; Yuan, Yuexing; Lin, Zuan-Tao; Li, Yaxi; Qiu, Jingyi; Xing, Yikun; Haley, Christopher; Tyring, Stephen K.; Wu, Tianfu

doi:10.1111/exd.13727

Cited by 9 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… 30 Since VEGF has been known to be involved in psoriasis pathogenesis, these reports support the hypothesis that miR-205 and miR-17 expressions may affect psoriasis development via VEGF. 31 In the present study, while miR-205-5p expression was significantly up-regulated, mir-17-3p expression was significantly down-regulated in psoriasis patients when compared with controls.…”

Section: Discussionsupporting

confidence: 44%

Blood microRNA expressions in patients with mild to moderate psoriasis and the relationship between microRNAs and psoriasis activity

Alataş

Kara

Doğan

et al. 2020

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

Background In recent studies, microRNAs (mi-RNAs) have been shown to play an important role in psoriasis pathogenesis. However, studies evaluating mi-RNAs in the blood of psoriasis patients including a large number of mi-RNA panels are scarce. Objective The authors aimed to assess mi-RNA expressions in blood samples of psoriasis patients, as well as to evaluate the association between mi-RNA expression and psoriasis severity. Methods This was a case-control study on 52 patients with psoriasis vulgaris and 54 controls. Patients’ medical history, psoriasis area and severity index (PASI) scores, and dermatology life quality index (DLQI) scores were recorded. The 42 disease-related mi-RNA primers were assessed by real-time PCR. Results In the patient group, 13.4% presented nail involvement and 8.2% had psoriatic arthritis. The mean PASI and DLQI scores were 7.90 ± 8.83 and 8.13 ± 5.50, respectively. Among 42 mi-RNA primers; hsa-miR-155-5p, hsa-miR-369-3p, hsa-miR-193b-3p, hsa-miR-498, hsa-miR-1266-5p, hsa-let-7d-5p, hsa-miR-205-5p, hsa-let-7c-5p, hsa-miR-30b-3p, and hsa-miR-515-3p expressions were significantly up-regulated, whereas hsa-miR-21-5p, hsa-miR-142-3p, hsa-miR-424-5p, hsa-miR-223-3p, hsa-miR-26a-5p, hsa-miR-106b-5p, hsa-miR-126-5p, hsa-miR-181a-5p, hsa-miR-222-3p, hsa-miR-22-3p, hsa-miR-24-3p, hsa-miR-17-3p, hsa-miR-30b-5p, hsa-miR-130a-3p, hsa-miR-30e-5p, and hsa-miR-16-5p were significantly down-regulated in psoriasis patients when compared with the control group ( p < 0.05). Study limitations As the study included patients with mild to moderate psoriasis who mostly only received topical treatments, changes in miRNA before and after systemic treatments were not assessed. Conclusion The detection of 24 mi-RNA expressions up- or down-regulated in psoriasis patients, even in those with milder disease, further supports the role of mi-RNAs in the psoriasis pathogenesis. Future studies should clarify whether mi-RNAs can be used as a marker for psoriasis prognosis or as a therapeutic agent in the treatment of psoriasis.

show abstract

Section: Discussionsupporting

confidence: 44%

Blood microRNA expressions in patients with mild to moderate psoriasis and the relationship between microRNAs and psoriasis activity

Alataş

Kara

Doğan

et al. 2020

Anais Brasileiros de Dermatologia

View full text Add to dashboard Cite

show abstract

“…The neuropilins (NRPs), NRP-1 and NRP-2, are a family of non-tyrosine kinase receptors that amplify VEGF-A signalling. [38] Other members of the VEGF superfamily, such as VEGF-C and VEGF-D, bind to VEGFR-3 (also known as Flt-4), which is expressed in lymphatic endothelial cells and mediates lymphangiogenesis [39,40] ( Figure 2).…”

Section: Veg F-a B Iology: Synops Ismentioning

confidence: 99%

Vascular endothelial growth factor‐A as a promising therapeutic target for the management of psoriasis

Luengas‐Martinez

Hardman‐Smart

Paus

et al. 2020

Experimental Dermatology

View full text Add to dashboard Cite

Vascular endothelial growth factor‐A (VEGF‐A), the main angiogenic mediator, plays a critical role in the pathogenesis of several inflammatory immune‐mediated diseases, including psoriasis. Even though anti‐angiogenic therapies, such as VEGF inhibitors, are licensed for the treatment of various cancers and eye disease, VEGF‐targeting interventions are not part of current psoriasis therapy. In this viewpoint essay, we argue that the existing preclinical research evidence on the role of VEGF‐A in the pathogenesis of psoriasis as well as clinical observations in patients who have experienced psoriasis remission during oncological anti‐VEGF‐A therapy strongly suggests to systematically explore angiogenesis targeting also in the management of psoriasis. We also point out that some psoriasis therapies decrease circulating levels of VEGF‐A and normalise the psoriasis‐associated vascular pathology in the papillary dermis of plaques of psoriasis and that a subset of patients with constitutionally high levels of VEGF‐A may benefit most from the anti‐angiogenic therapy we advocate here. Given that novel, well‐targeted personalised medicine therapies for the development of psoriasis need to be developed, we explore the hypothesis that VEGF‐A and signalling through its receptors constitute a promising target for therapeutic intervention in the future management of psoriasis.

show abstract

“…Comprehensive determination of the serum proteome of psoriasis patients may help better understand the pathogenesis of psoriasis as well as identify diagnosis and treatment biomarkers. To date, only a limited number of psoriasis serum proteins have been studied 25, 26.…”

Section: Introductionmentioning

confidence: 99%

In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine

Xu¹,

Deng²,

Xu³

et al. 2019

Theranostics

View full text Add to dashboard Cite

Serum and plasma contain abundant biological information that reflect the body's physiological and pathological conditions and are therefore a valuable sample type for disease biomarkers. However, comprehensive profiling of the serological proteome is challenging due to the wide range of protein concentrations in serum. Methods : To address this challenge, we developed a novel in-depth serum proteomics platform capable of analyzing the serum proteome across ~10 orders or magnitude by combining data obtained from Data Independent Acquisition Mass Spectrometry (DIA-MS) and customizable antibody microarrays. Results : Using psoriasis as a proof-of-concept disease model, we screened 50 serum proteomes from healthy controls and psoriasis patients before and after treatment with traditional Chinese medicine (YinXieLing) on our in-depth serum proteomics platform. We identified 106 differentially-expressed proteins in psoriasis patients involved in psoriasis-relevant biological processes, such as blood coagulation, inflammation, apoptosis and angiogenesis signaling pathways. In addition, unbiased clustering and principle component analysis revealed 58 proteins discriminating healthy volunteers from psoriasis patients and 12 proteins distinguishing responders from non-responders to YinXieLing. To further demonstrate the clinical utility of our platform, we performed correlation analyses between serum proteomes and psoriasis activity and found a positive association between the psoriasis area and severity index (PASI) score with three serum proteins (PI3, CCL22, IL-12B). Conclusion : Taken together, these results demonstrate the clinical utility of our in-depth serum proteomics platform to identify specific diagnostic and predictive biomarkers of psoriasis and other immune-mediated diseases.

show abstract

Serum vascular endothelial growth factor receptor 3 as a potential biomarker in psoriasis

Cited by 9 publications

References 24 publications

Blood microRNA expressions in patients with mild to moderate psoriasis and the relationship between microRNAs and psoriasis activity

Blood microRNA expressions in patients with mild to moderate psoriasis and the relationship between microRNAs and psoriasis activity

Vascular endothelial growth factor‐A as a promising therapeutic target for the management of psoriasis

In-depth serum proteomics reveals biomarkers of psoriasis severity and response to traditional Chinese medicine

Contact Info

Product

Resources

About